Women's opinions on the home management of early medical abortion in the UK

Journal of Family Planning and Reproductive Health Care

Volumn 36, Issue 1, 2010, Pages 21-25

  Lohr, Patricia A ^a   Wade, Josephine ^a   Riley, Laura ^a   Fitzgibbon, Abigail ^a   Furedi, Ann ^a  

^a British Pregnancy Advisory Service   (United Kingdom)

Author keywords

Acceptability; Home administration; Medical abortion; Mifepristone; Misoprostol

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ADOLESCENT; ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GESTATIONAL AGE; HEALTH SURVEY; HOME MONITORING; HOSPITAL; HUMAN; MEDICAL ABORTION; STRUCTURED QUESTIONNAIRE; UNITED KINGDOM;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADOLESCENT; ADULT; ATTITUDE TO HEALTH; FEMALE; GREAT BRITAIN; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MIFEPRISTONE; MISOPROSTOL; PATIENT SATISFACTION; PREGNANCY; QUESTIONNAIRES; SELF CARE; YOUNG ADULT;

EID: 76149134733     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118910790290894     Document Type: Article

References (15)

1. Abortion Act 1967 (c. 87). http://www.statutelaw.gov.uk [Accessed 24 July 2009].
2. Ingham R, Lee E. Evaluation of Early Medical Abortion (EMA) Pilot Sites. London, UK: Department of Health, 2008.
3. Fiala C, Winikoff B, Helström L, Hellborg M, Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical abortion. Contraception 2004; 70: 387-392.
4. Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur J Contracept Reprod Health Care 2005; 10: 184-191.
5. Guengant JP, Bangou J, Elul B, Ellertson C. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe. Contraception 1999; 60: 167-172.
6. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000; 284: 1948-1953.
7. Ngoc NT, Nhan VQ, Blum J, Mai TT, Durocher JM, Winikoff B. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. Br J Obstet Gynaecol 2004; 111: 814-819.
8. Thong KJ, Dewar MH, Baird DT. What do women want during medical abortion? Contraception 1992; 46: 435-442.
9. Hamoda H, Critchley HOD, Paterson K, Guthrie K, Rodger M, Penney GC. The acceptability of home medical abortion to women in UK settings. Br J Obstet Gynaecol 2005; 112: 781-785.
10. Hamoda H, Ashok PW, Flett GMM, Templeton A. Home self-administration of misoprostol for medical abortion up to 56 days' gestation. J Fam Plann Reprod Health Care 2005; 31: 189-192.
11. Teal SB, Dempsey-Fanning A, Westhoff C. Predictors of acceptability of medication abortion. Contraception 2007; 75: 224-229.
12. Ho PC. Women's perceptions on medical abortion. Contraception 2006; 74: 11-15.
13. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. Arch Fam Med 1998; 7: 360-366.
14. Department of Health. Abortion Statistics, England and Wales: 2008 (Statistical Bulletin 2009/1). London, UK: Department of Health, 2009.
15. Department of Health. Evaluation of Early Medical Abortion (EMA) Pilot Sites: Final Report. London, UK: Department of Health, 2008.